Locations:
Search IconSearch

Multiple Sclerosis

21-NEU-2474109_mesenchymal-stem-cells_650x450

Intrathecally Delivered Enhanced Stem Cells Show Promise in Progressive MS

Phase 2 clinical study supports safety and efficacy of MSC-NTFs

21-NEU-2259158 MS-in-Black-Americans_650x450

Black Americans Suffer Greater Multiple Sclerosis Disease Burden Than Whites

Database study reveals racial differences across clinical and imaging domains

21-NEU-2245408_mri-in-MS_650x450

How Well Do Current MRI Modalities Measure Cortical Lesion Load in Multiple Sclerosis?

Shortcomings in specificity show influence of cortical changes beyond demyelination

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

thalamic lesions in multiple sclerosis

Deep Gray Matter Injury in Multiple Sclerosis: What We Know, Why It Matters

A new NAIMS consensus statement summarizes evidence, guides MRI investigation

21-NEU-2079842_COVID-19-in-MS-patients_650x450
March 29, 2021/COVID-19

Registry Study Pinpoints Risk Factors for Worse COVID-19 Outcomes in Patients With MS

Ambulation disability carries greatest risk, most disease-modifying therapies aren’t implicated

brain MRI hereditary spastic paraplegia
March 9, 2021/Genomic Medicine

Learning from Multiple Sclerosis Misdiagnosis: Insights Into Genetic Leukodystrophies

Clinical cohort study helps define red flags for these rare MS mimics

21-NEU-2050870_woman-in-wheelchair_650x450

How Do Patients With Multiple Sclerosis Perceive the U.S. Drug Approval Process?

Survey suggests need for education about FDA’s mission, trustworthiness

21-NEU-2046760_CQD_650x450_200158799_with mask

In Patients With NMOSD, Early Age at Onset Is Associated With Severity of Visual Loss

Large cohort study supports early consideration of aggressive therapy

20-NEU-2023067 hand spasticity_650x450

Cannabis Extract Improves Spasticity Without Increasing Weakness in Patients With MS

Cannabinoid oromucosal spray is poised for FDA submission in 2021

BackPage 3 of 3Next

Advertisement

Ad